Johnson & Johnson Projects $10B Tremfya Sales as IMAAVY Shows 3x Hemoglobin Gains
JNJ•Johnson & Johnson’s Innovative Medicines unit grew operational sales by 4.2% in April despite an 810-basis-point STELARA decline, led by Tremfya’s launch (projected >$10 billion peak sales) and Caplyta ($5 billion-plus potential). IMAAVY met its Phase 2/3 wAIHA endpoint, tripling hemoglobin response odds and earning FDA Priority Review.
1. Operational Sales Resilience
In April, J&J’s Innovative Medicines division delivered 4.2% operational sales growth despite an estimated 810-basis-point decline from STELARA’s patent expiry. Strong uptake of Tremfya and Caplyta offset generic competition.
2. Tremfya and Caplyta Forecasts
Management projects Tremfya to exceed $10 billion in peak annual sales and Caplyta to reach at least $5 billion, highlighting robust immunology and CNS pipelines. Internal forecasts for oral peptide Icotrokinra also exceed street estimates by over 100%.
3. Financial Outlook Discrepancy
The finance chief publicly showcased internal models that surpass consensus estimates by 25% for Tremfya and twofold for Icotrokinra, signaling potential undervaluation. This disclosure aimed to correct market assumptions ahead of valuation reratings.
4. IMAAVY Clinical Success and FDA Review
IMAAVY achieved its primary endpoint in the Phase 2/3 ENERGY trial for warm autoimmune hemolytic anemia, with the 30 mg/kg arm tripling the odds of durable hemoglobin improvements and reducing steroid use. The FDA has granted Priority Review for its supplemental BLA.
